Live feed02:30:00·31dPRReleasevia QuantisnowNew Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease BurdenByQuantisnow·Wall Street's wire, on your screen.ALNY· Alnylam Pharmaceuticals Inc.Health Care
